204 related articles for article (PubMed ID: 29339403)
1. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
Sun W; Triche T; Malvar J; Gaynon P; Sposto R; Yang X; Bittencourt H; Place AE; Messinger Y; Fraser C; Dalla-Pozza L; Salhia B; Jones P; Wayne AS; Gore L; Cooper TM; Liang G
Blood; 2018 Mar; 131(10):1145-1148. PubMed ID: 29339403
[No Abstract] [Full Text] [Related]
2. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
3. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
4. Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia.
Ramakrishnan R; Munir F; Quesada AE; Hitzler J; Cuglievan B
Pediatr Blood Cancer; 2024 Jun; 71(6):e30974. PubMed ID: 38523255
[No Abstract] [Full Text] [Related]
5. Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
Kearns P; Zwaan CM; Reinhardt D; Gibson B; Moreno L; Nysom K; Nakahara S; Huang F; Zhou W; Parasrampuria DA; Nemat S
Br J Haematol; 2019 Aug; 186(3):e7-e11. PubMed ID: 30847896
[No Abstract] [Full Text] [Related]
6. How I treat older patients with acute myeloid leukemia.
Arellano M; Carlisle JW
Cancer; 2018 Jun; 124(12):2472-2483. PubMed ID: 29809277
[No Abstract] [Full Text] [Related]
7. A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.
Zheng H; Mineishi S; Claxton D; Zhu J; Zhao C; Jia B; Ehmann WC; Rybka WB; Naik S; Songdej N; Drabick JJ; Hohl RJ
Am J Hematol; 2021 Feb; 96(2):E46-E50. PubMed ID: 33146922
[No Abstract] [Full Text] [Related]
8. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
11. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
12. Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Zhang X; Guo X
Ann Hematol; 2019 Sep; 98(9):2223-2225. PubMed ID: 30980106
[No Abstract] [Full Text] [Related]
13. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Fathi AT; Erba HP; Lancet JE; Stein EM; Ravandi F; Faderl S; Walter RB; Advani AS; DeAngelo DJ; Kovacsovics TJ; Jillella A; Bixby D; Levy MY; O'Meara MM; Ho PA; Voellinger J; Stein AS
Blood; 2018 Sep; 132(11):1125-1133. PubMed ID: 30045838
[TBL] [Abstract][Full Text] [Related]
15. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
Österroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Möllgård L; Derolf ÅR; Uggla B; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
Br J Haematol; 2020 Apr; 189(1):e13-e16. PubMed ID: 32103493
[No Abstract] [Full Text] [Related]
17. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
[TBL] [Abstract][Full Text] [Related]
18. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Welch JS; Klco JM; Gao F; Procknow E; Uy GL; Stockerl-Goldstein KE; Abboud CN; Westervelt P; DiPersio JF; Hassan A; Cashen AF; Vij R
Am J Hematol; 2011 Sep; 86(9):796-800. PubMed ID: 21815182
[No Abstract] [Full Text] [Related]
19. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
20. A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia.
Zhu LX; Chen RR; Wang LL; Sun JN; Zhou D; Li L; Qian JJ; Zhang Y; Tong HY; Yu WJ; Meng HT; Mai WY; Xie WZ; Jin J; Ye XJ; Zhu HH
Support Care Cancer; 2022 Aug; 30(8):7031-7038. PubMed ID: 35585204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
